North America Vagus Nerve Stimulation Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

North America Vagus Nerve Stimulation Market Overview

The North America vagus nerve stimulation market was valued at USD 537.37 million in 2025 and is projected to reach USD 2,019.89 million by 2033, growing at a CAGR of 18.00% from 2026 to 2033. The market is witnessing steady expansion driven by the rising prevalence of epilepsy, treatment-resistant depression, and other neurological disorders, along with increasing adoption of implantable neuromodulation therapies. Strong healthcare infrastructure, high patient awareness, and favorable reimbursement frameworks are further supporting market penetration across the region.

The growing shift toward minimally invasive and advanced bioelectronic therapies is accelerating demand for next-generation VNS devices, including closed-loop and MRI-compatible systems. Increasing clinical evidence supporting long-term efficacy, coupled with expanding applications in anxiety disorders, Alzheimer’s disease, and chronic inflammatory conditions, is encouraging broader adoption among neurologists and hospitals. In addition, ongoing R&D investments by key medical device manufacturers and increasing FDA approvals are expected to strengthen market growth over the forecast period.

Key Market Trends & Insights

• The United States dominated the North America vagus nerve stimulation market with the largest revenue share of 85.8% in 2025, supported by strong FDA approvals, advanced neuromodulation infrastructure, and high adoption of implantable neurostimulation therapies.
• The Implantable VNS Devices segment led the market with a 72.4% share in 2025, driven by its strong clinical effectiveness in treating drug-resistant epilepsy and treatment-resistant depression.
• Canada is expected to be the fastest-growing country at a CAGR of 7.8% from 2026 to 2033, fueled by expanding access to neurology care, increasing adoption of advanced epilepsy and depression treatments, and improving reimbursement support for neuromodulation devices.
• External VNS Devices are the fastest-growing product type, projected to register a CAGR of 9.2%, reflecting the surge in demand for non-invasive and wearable neuromodulation therapies.
• The Metallic segment dominated the biomaterial category with a 58.6% revenue share in 2025, led by its superior electrical conductivity, durability, and long-term stability in implantable devices.
• Epileptic Seizures accounted for 46.8% of the market, preferred by the strong clinical validation of VNS therapy for drug-resistant epilepsy.
• The Depression and Anxiety segment is the fastest-growing application category, with a CAGR of 10.1%, driven by rising mental health disorders across North America. Increasing cases of treatment-resistant depression are driving adoption of VNS therapy.

Market Size & Forecast

• Global Market Value (2025): USD 537.37 Million
• Expected Market Value (2033): USD 2,019.89 Million
• Forecast CAGR (2026–2033): 18.00%
• Leading Country in 2025: United States
• Fastest Growing Country: Canada

Report Scope and North America Vagus Nerve Stimulation Market Segmentation

North America Vagus Nerve Stimulation Market Trends

Trend: Expansion of Neuromodulation in Neuropsychiatric Care

Vagus nerve stimulation is increasingly being adopted for treatment-resistant depression and other neuropsychiatric disorders as clinical evidence supports long-term efficacy and safety. Hospitals and specialty neurology centers are integrating VNS into broader neuromodulation programs alongside deep brain stimulation and transcranial therapies. The use of implantable and closed-loop devices is improving treatment personalization through real-time neural feedback and adaptive stimulation settings. Growing patient acceptance and physician confidence are further accelerating adoption across complex neurological conditions, while digital health integration enhances post-implant monitoring and therapy optimization. for instance, clinical use of FDA-approved VNS Therapy systems by LivaNova in refractory epilepsy and depression management programs across U.S. hospitals.

North America Vagus Nerve Stimulation Market Dynamics

Key Market Driver: Growing Adoption of Simulation in Autonomous Vehicle Development

The increasing prevalence of drug-resistant epilepsy and treatment-resistant depression is significantly driving demand for vagus nerve stimulation therapies across North America. Patients who do not respond adequately to pharmacological treatments are increasingly being referred for implantable neuromodulation procedures. Strong clinical guidelines and reimbursement support from public and private insurers are further encouraging adoption among healthcare providers. Continuous advancements in device miniaturization and stimulation precision are improving patient outcomes and widening eligibility criteria. for instance, expanded Medicare and FDA-supported use of VNS Therapy for drug-resistant epilepsy patients in the United States

Key Restraint/Challenge: High Procedural and Device Cost Barriers

The high cost of vagus nerve stimulation devices and associated surgical implantation procedures remains a major barrier to broader adoption across North America. The overall treatment cost includes device procurement, hospital charges, neurosurgical expertise, and long-term maintenance, making it less accessible for uninsured or underinsured patients. Smaller healthcare facilities also face challenges in establishing the required surgical infrastructure and post-operative monitoring systems. Despite reimbursement availability, out-of-pocket expenses can still limit patient uptake in certain segments. for instance, limited adoption of implantable VNS systems in small outpatient neurology clinics due to high upfront procedural and device costs in the United States

Key Market Opportunity: Expansion of Closed-Loop and AI-Enabled Neuromodulation Systems

The integration of closed-loop stimulation and AI-based analytics presents a major growth opportunity in the North America vagus nerve stimulation market. These advanced systems enable real-time monitoring of neural signals and adaptive adjustment of stimulation parameters, improving therapeutic outcomes for epilepsy and depression patients. Increasing investment in digital health platforms and connected implantable devices is further enhancing remote monitoring and long-term care management. Collaboration between medical device companies and AI technology providers is accelerating innovation in personalized neuromodulation therapies. for instance, development of next-generation responsive VNS systems with real-time seizure detection algorithms used in advanced epilepsy care programs in the United States

North America Vagus Nerve Stimulation Market Scope

The North America vagus nerve stimulation market is segmented on the basis of product type, biomaterial, application, patient type, end user, and distribution channel.

• By Product Type

On the basis of product type, the North America VNS market is segmented into implantable VNS devices and external VNS devices. The Implantable VNS Devices segment dominated the market in 2025, accounting for 72.4% share, due to its strong clinical effectiveness in treating drug-resistant epilepsy and treatment-resistant depression. These devices provide continuous, long-term nerve stimulation, which improves patient outcomes and reduces recurrence of symptoms. High adoption across hospitals and specialty neurology centers further strengthens this segment. Strong FDA approvals and established reimbursement frameworks make implantable devices the preferred choice. In addition, growing awareness among neurologists about long-term neuromodulation benefits continues to reinforce dominance.

The External VNS Devices segment is expected to register the fastest growth at a CAGR of 9.2% during 2026–2033, driven by rising demand for non-invasive and wearable neuromodulation therapies. These devices eliminate the need for surgical implantation, reducing risks and recovery time. Increasing adoption for indications such as migraine, anxiety, and short-term pain management is boosting demand. Technological advancements in wearable stimulation devices are improving patient comfort and usability. Expansion of home healthcare and telehealth services is further accelerating growth. Growing preference for patient-controlled therapy solutions is also supporting rapid expansion.

• By Biomaterial

On the basis of biomaterial, the market is segmented into ceramics, metallic, and polymeric materials. The Metallic segment dominated the North America VNS market in 2025, accounting for 58.6% share, due to its superior electrical conductivity, durability, and long-term stability in implantable devices. Metals such as platinum-iridium are widely used in electrodes to ensure precise nerve stimulation. These materials are highly biocompatible and resistant to corrosion, making them ideal for long-term implantation. Most commercially available VNS systems rely heavily on metallic components for signal transmission. Strong clinical reliability and long device lifespan further strengthen this segment. Continuous innovation in medical-grade alloys also supports sustained dominance.

The Polymeric segment is expected to register the fastest growth at a CAGR of 8.4% during 2026–2033, driven by increasing demand for flexible, lightweight, and cost-effective biomaterials. Polymeric coatings and insulation materials are widely used in both implantable and external devices. These materials improve patient comfort and reduce tissue irritation. Advancements in medical-grade polymers are enhancing safety and device compatibility. Rising adoption of wearable neurostimulation devices is further boosting demand. In addition, increasing R&D in biocompatible materials is accelerating segment growth.

• By Application

On the basis of application, the market is segmented into pain management, epileptic seizures, obesity management, depression and anxiety, and others. The Epileptic Seizures segment dominated the market in 2025, accounting for 46.8% share, due to strong clinical validation of VNS therapy for drug-resistant epilepsy. It is widely recommended as an adjunct treatment when medication fails to control seizures. High prevalence of epilepsy across North America supports consistent demand. Strong reimbursement coverage and physician acceptance further reinforce this segment. Hospitals and neurology clinics widely use VNS devices for seizure reduction. Long-term clinical evidence of improved patient outcomes continues to strengthen dominance.

The Depression and Anxiety segment is expected to register the fastest growth at a CAGR of 10.1% during 2026–2033, due to rising mental health disorders across North America. Increasing cases of treatment-resistant depression are driving adoption of VNS therapy. Growing awareness of neuromodulation as an alternative to pharmaceuticals is supporting demand. Clinical studies showing mood stabilization benefits are improving acceptance. Expansion of mental health services and telepsychiatry is further accelerating usage. Rising focus on non-drug treatment options is a major growth driver.

• By Patient Type

On the basis of patient type, the market is segmented into adults, pediatric, and geriatric. The Adults segment dominated the North America VNS market in 2025, accounting for 68.9% share, due to the highest prevalence of epilepsy and depression in this population group. Most VNS implant procedures are performed in adults because of higher diagnosis rates and better surgical eligibility. Strong insurance coverage and established treatment pathways further support adoption. Neurologists widely recommend VNS therapy for adult patients with refractory conditions. Higher treatment compliance and better clinical outcomes also reinforce dominance. Hospitals primarily focus on adult neuromodulation therapies, strengthening this segment.

The Geriatric segment is expected to register the fastest growth at a CAGR of 9.0% during 2026–2033, due to increasing neurological disorders among the aging population. Elderly patients are more susceptible to epilepsy, chronic pain, and depression. Advancements in minimally invasive VNS technologies are improving safety for older patients. Growing geriatric healthcare infrastructure is supporting adoption. Rising life expectancy in North America is further expanding the patient base. Increasing focus on elderly mental health is also contributing to strong growth.

• By End User

On the basis of end user, the market is segmented into hospitals, ambulatory surgery centres, specialty centers, and others. The Hospitals segment dominated the North America VNS market in 2025, accounting for 61.2% share, due to advanced surgical infrastructure and availability of skilled neurologists. Most implantable VNS procedures are performed in hospital settings. Strong reimbursement systems and insurance coverage support patient access. Hospitals also provide comprehensive pre- and post-operative care, improving treatment outcomes. High patient inflow for neurological disorders further strengthens dominance. Integration of advanced diagnostic systems also supports this segment.

The Ambulatory Surgery Centres (ASCs) segment is expected to register the fastest growth at a CAGR of 9.5% during 2026–2033, due to increasing shift toward outpatient and minimally invasive procedures. ASCs offer lower treatment costs and faster recovery times compared to hospitals. Technological improvements in VNS implantation procedures are enabling same-day discharge. Rising patient preference for convenient care settings is boosting demand. Expansion of decentralized healthcare services is further supporting growth. Increasing investment in outpatient neurosurgical infrastructure is accelerating adoption.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. The Direct Tender segment dominated the North America VNS market in 2025, accounting for 66.8% share, due to bulk procurement by hospitals and government healthcare systems. This channel ensures cost efficiency and standardized supply of devices. Large manufacturers prefer direct contracts for stable long-term revenue. Strong institutional purchasing frameworks support high-volume adoption. Regulatory compliance and reimbursement alignment further strengthen this segment. Hospitals primarily rely on tender-based procurement for implantable devices.

The Retail Sales segment is expected to register the fastest growth at a CAGR of 8.7% during 2026–2033, due to rising availability of external VNS devices for home use. Increasing penetration of e-commerce platforms and medical retail channels is improving accessibility. Patients are showing higher preference for non-invasive, self-managed therapies. Growing awareness of wearable neurostimulation devices is supporting demand. Expansion of digital healthcare ecosystems is further accelerating adoption. Rising consumer interest in at-home neurological care is a key growth driver.

North America Vagus Nerve Stimulation Market Regional Analysis

The United States dominated the North America vagus nerve stimulation market with the largest revenue share of 85.8% in 2025, supported by strong FDA approvals, advanced neuromodulation infrastructure, and high adoption of implantable neurostimulation therapies. The country benefits from a high burden of neurological disorders, particularly drug-resistant epilepsy and treatment-resistant depression, which significantly drives demand for VNS therapy. Strong FDA approvals, well-established reimbursement structures, and early commercialization of innovative neurostimulation technologies further strengthen market growth. The U.S. also leads in clinical research, adoption of next-generation external VNS devices, and integration of neuromodulation in psychiatric care pathways. Increasing healthcare expenditure, rising awareness of non-pharmacological treatment options, and expansion of specialty neurology centers continue to reinforce the country’s dominance in the North America Vagus Nerve Stimulation market.

U.S. Vagus Nerve Stimulation Market Insight

The U.S. Vagus Nerve Stimulation market is witnessing strong growth due to rising prevalence of drug-resistant epilepsy, treatment-resistant depression, and increasing adoption of advanced neuromodulation therapies. The country’s highly developed healthcare infrastructure, along with strong presence of leading medical device manufacturers, is driving widespread use of implantable VNS systems. Expanding FDA approvals, favorable reimbursement coverage, and early adoption of innovative external VNS devices are further supporting market expansion. In addition, growing focus on mental health treatment, increasing investments in neurotechnology research, and rising integration of VNS in psychiatric and neurological care pathways are accelerating adoption across hospitals and specialty centers.

Canada Vagus Nerve Stimulation Market Insight

The Canada Vagus Nerve Stimulation market is experiencing steady growth, supported by increasing prevalence of neurological disorders and rising adoption of advanced neurostimulation therapies. Strong public healthcare coverage and expanding access to specialized neurology services are supporting the use of VNS devices, particularly for epilepsy and treatment-resistant depression. Growing awareness of non-pharmacological treatment options is further driving demand across hospitals and specialty clinics. In addition, increasing investments in mental health care, rising clinical research activity in neuromodulation, and gradual adoption of external VNS devices are contributing to market expansion across the country.

Mexico Vagus Nerve Stimulation Market Insight

The Mexico Vagus Nerve Stimulation market is growing steadily, driven by improving healthcare infrastructure and increasing awareness of neurological disorder treatments. Rising cases of epilepsy and mental health conditions are supporting gradual adoption of VNS therapy in urban healthcare centers. Expansion of private hospitals and specialty neurology clinics is further enhancing access to advanced treatment options. In addition, increasing medical tourism, growing healthcare investments, and gradual introduction of neuromodulation technologies are supporting market development. However, limited reimbursement coverage and high device costs continue to restrain faster adoption across the broader population.

North America Vagus Nerve Stimulation Market Share

The North America vagus nerve stimulation industry is primarily led by well-established companies, including:

• LivaNova PLC (U.K.)
• electroCore, Inc. (U.S.)
• SetPoint Medical Corporation (U.S.)
• MicroTransponder Inc. (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• NeuroPace, Inc. (U.S.)
• Cyberonics (U.S.)
• GSK plc (U.K.)
• Integer Holdings Corporation (U.S.)
• Axonics, Inc. (U.S.)
• Synapse Biomedical Inc. (U.S.)
• Soterix Medical Inc. (U.S.)
• NeuroSigma, Inc. (U.S.)
• Parasym Ltd (U.K.)
• BIOTRONIK SE & Co. KG (Germany)
• NeuroMetrix, Inc. (U.S.)
• Nevro Corp. (U.S.)
• Sorin Group (Italy)

Latest Developments in North America Vagus Nerve Stimulation Market

• In July 2025, the U.S. Food and Drug Administration (FDA) approved the first vagus nerve stimulation device for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients who do not respond adequately to biologic or targeted synthetic disease-modifying antirheumatic drugs. This approval marked a major expansion of VNS therapy beyond neurological disorders into autoimmune disease management. The device works by stimulating the vagus nerve to help regulate inflammatory responses in the body, opening a new pathway for bioelectronic medicine in North America
• In March 2022, electroCore Inc. reported expanding adoption of gammaCore non-invasive VNS therapy across U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) healthcare facilities. This growth reflected increasing integration of neuromodulation therapies into federal healthcare systems for headache and neurological disorder management. Rising prescription rates indicated stronger physician confidence in external VNS devices as a non-pharmacological treatment option. The development supported broader commercialization of bioelectronic medicine in North America
• In September 2021, electroCore Inc. announced that the U.S. FDA granted 510(k) clearance for expanded use of gammaCore VNS therapy for the treatment of hemicrania continua and paroxysmal hemicrania in adults. This development broadened the clinical scope of non-invasive vagus nerve stimulation in rare and refractory headache disorders. It strengthened adoption in neurology practices by offering new treatment pathways for patients with limited therapeutic options. The expansion highlighted increasing regulatory support for bioelectronic medicine in North America
• In May 2021, electroCore Inc. announced collaboration with the U.S. Department of Veterans Affairs (VA) to evaluate gammaCore non-invasive VNS therapy for post-traumatic headache management in military veterans. This initiative focused on patients suffering from traumatic brain injury-related chronic headaches, a common condition among veterans. The study represented growing government interest in neuromodulation therapies for complex neurological conditions. It also expanded clinical research applications of VNS beyond traditional epilepsy and migraine indications
• In February 2021, electroCore Inc., a leading bioelectronic medicine company in North America, announced that the U.S. FDA granted 510(k) clearance for its gammaCore non-invasive VNS therapy for the acute and preventive treatment of migraine in adolescents aged 12–17 years. This approval significantly expanded the pediatric neuromodulation market in the U.S., enabling broader clinical use of external vagus nerve stimulation devices in younger patients suffering from chronic migraine. The development strengthened adoption of non-invasive VNS as a drug-free treatment option and supported earlier intervention strategies in neurological care

SKU-69407